Home > Publications database > FOXR2 Stabilizes MYCN Protein and Identifies Non-MYCN-Amplified Neuroblastoma Patients With Unfavorable Outcome. > print

001     169155
005     20240229133642.0
024 7 _ |a 10.1200/JCO.20.02540
|2 doi
024 7 _ |a pmid:34110923
|2 pmid
024 7 _ |a 0732-183X
|2 ISSN
024 7 _ |a 1527-7755
|2 ISSN
024 7 _ |a altmetric:107555718
|2 altmetric
037 _ _ |a DKFZ-2021-01289
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Schmitt-Hoffner, Felix
|0 P:(DE-He78)fce464e68d8888e5e7be72b7a197bca7
|b 0
|e First author
|u dkfz
245 _ _ |a FOXR2 Stabilizes MYCN Protein and Identifies Non-MYCN-Amplified Neuroblastoma Patients With Unfavorable Outcome.
260 _ _ |a Alexandria, Va.
|c 2021
|b American Society of Clinical Oncology
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1634566842_4000
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:B062#LA:B062#/ 2021 Oct 10;39(29):3217-3228
520 _ _ |a Clinical outcomes of patients with neuroblastoma range from spontaneous tumor regression to fatality. Hence, understanding the mechanisms that cause tumor progression is crucial for the treatment of patients. In this study, we show that FOXR2 activation identifies a subset of neuroblastoma tumors with unfavorable outcome and we investigate the mechanism how FOXR2 relates to poor outcome in patients.We analyzed three independent transcriptional data sets of in total 1030 primary neuroblastomas with full clinical annotation. We performed immunoprecipitation for FOXR2 and MYCN and silenced FOXR2 expression in two neuroblastoma cell lines to examine the effect on cellular processes, transcriptome, and MYCN protein levels. Tumor samples were analyzed for protein levels of FOXR2 and MYCN.In three combined neuroblastoma data sets, 9% of tumors show expression of FOXR2 but have low levels of MYCN mRNA. FOXR2 expression identifies a group of patients with unfavorable outcome, showing 10-year overall survival rates of 53%-59%, and proves to be an independent prognostic factor compared with established risk factors. Transcriptionally, FOXR2-expressing tumors are very similar to MYCN-amplified tumors, suggesting that they might share a common mechanism of tumor initiation. FOXR2 knockdown in FOXR2-expressing neuroblastoma cell lines resulted in cell cycle arrest, reduced cell growth, cell death, and reduced MYCN protein levels, all indicating that FOXR2 is essential for these tumors. Finally, we show that FOXR2 binds and stabilizes MYCN protein and MYCN protein levels are highly increased in FOXR2-expressing tumors, in several cases comparable with MYCN-amplified samples.The stabilization of MYCN by FOXR2 represents an alternative mechanism to MYCN amplification to increase MYCN protein levels. As such, FOXR2 expression identifies another subset of neuroblastoma patients with unfavorable clinical outcome.
536 _ _ |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312)
|0 G:(DE-HGF)POF4-312
|c POF4-312
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
700 1 _ |a van Rijn, Sjoerd
|0 P:(DE-He78)6f3ac5e773e94ee6127aaba91db70b25
|b 1
700 1 _ |a Toprak, Umut H
|0 P:(DE-He78)cd8295952c28dc5b483b5ba9386a5669
|b 2
|u dkfz
700 1 _ |a Mauermann, Monika
|0 P:(DE-He78)c865b84c0142dfa1def7dfeb70302918
|b 3
|u dkfz
700 1 _ |a Rosemann, Felix
|0 P:(DE-He78)c5791cc5875e5a2a7f950b79f5912a4f
|b 4
700 1 _ |a Heit-Mondrzyk, Anke
|0 P:(DE-He78)a3d2e48d4d32d6b3952996020fe8d1b5
|b 5
|u dkfz
700 1 _ |a Hübner, Jens-Martin
|0 P:(DE-He78)a8c698e0904394407c5261932915daa5
|b 6
|u dkfz
700 1 _ |a Camgöz, Aylin
|0 P:(DE-He78)dd60ad1c45db7fcacc5be5238ad17e7d
|b 7
|u dkfz
700 1 _ |a Hartlieb, Sabine
|0 P:(DE-He78)311fe8118b7563b455ba84e94fccb3a8
|b 8
|u dkfz
700 1 _ |a Pfister, Stefan M
|0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
|b 9
|u dkfz
700 1 _ |a Henrich, Kai-Oliver
|0 P:(DE-He78)a579ca2567736066534409e732b31c91
|b 10
|u dkfz
700 1 _ |a Westermann, Frank
|0 P:(DE-He78)91f32735ee876c579d63c05a7f4778dd
|b 11
|u dkfz
700 1 _ |a Kool, Marcel
|0 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8
|b 12
|e Last author
|u dkfz
773 _ _ |a 10.1200/JCO.20.02540
|g p. JCO.20.02540 -
|0 PERI:(DE-600)2005181-5
|n 29
|p 3217-3228
|t Journal of clinical oncology
|v 39
|y 2021
|x 1527-7755
909 C O |p VDB
|o oai:inrepo02.dkfz.de:169155
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)fce464e68d8888e5e7be72b7a197bca7
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)6f3ac5e773e94ee6127aaba91db70b25
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)cd8295952c28dc5b483b5ba9386a5669
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)c865b84c0142dfa1def7dfeb70302918
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)c5791cc5875e5a2a7f950b79f5912a4f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)a3d2e48d4d32d6b3952996020fe8d1b5
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)a8c698e0904394407c5261932915daa5
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)dd60ad1c45db7fcacc5be5238ad17e7d
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)311fe8118b7563b455ba84e94fccb3a8
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)a579ca2567736066534409e732b31c91
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-He78)91f32735ee876c579d63c05a7f4778dd
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 12
|6 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-312
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Funktionelle und strukturelle Genomforschung
|x 0
913 0 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-312
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Functional and structural genomics
|x 0
914 1 _ |y 2021
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2021-01-28
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2021-01-28
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2021-01-28
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J CLIN ONCOL : 2019
|d 2021-01-28
915 _ _ |a IF >= 30
|0 StatID:(DE-HGF)9930
|2 StatID
|b J CLIN ONCOL : 2019
|d 2021-01-28
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l B062 Pädiatrische Neuroonkologie
|x 0
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 1
920 1 _ |0 I:(DE-He78)B087-20160331
|k B087
|l B087 Neuroblastom Genomik
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a I:(DE-He78)B087-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21